Remed Co (XKRX:302550) Net Income From Continuing Operations : ₩319 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Remed Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Remed Co's net income from continuing operations for the three months ended in Dec. 2023 was ₩102 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ₩319 Mil.

Remed Co Net Income From Continuing Operations Historical Data

The historical data trend for Remed Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remed Co Net Income From Continuing Operations Chart

Remed Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

4,363.10

-1,833.71

752.33

3,951.25

319.25

Remed Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-1,216.26	200.53	-969.25	985.84	102.13

Remed Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩319 Mil.

Remed Co (XKRX:302550) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remed Co Ltd (XKRX:302550) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

187 Techno 2-ro, No 301-303, Gwanpyeong-dong, Yuseong-gu, Daejeon, KOR, 34025

Website

http://www.remed.kr

Remed Co Ltd is a Korean medical equipment manufacturing company. The company is engaged in researching and developing products to treat brain disorders such as depression, anxiety, stroke and Parkin's. It has developed TMS device and is manufacturing pain therapy devices using advanced electromagnetic stimulation, shockwave (RSWT) and laser technologies. Its products offerings include Transcranial Magnetic simulator for brain, Electromagnetic simulators including Salus Talent, Salus Talent A, Salus Talent Pro, and Optimus Pro for pain therapy; and Rosetta, Salus RSWT and Optimus Pro as a part of Extracorporeal Shockwave Therapy. It also offers Electrosurgical units from REMED including ELPIS 4L, ELPIS 4, ELPIS 3, and ELPIS2.

Remed Co (XKRX:302550) Headlines

No Headlines